Side by side
How the two compare across structure, mechanism studied, evidence and regulatory status, based on published research.
Melanotan I (Afamelanotide)
α-MSH analogue with photoprotective activity
View Melanotan I (Afamelanotide)| Property | Melanotan I (Afamelanotide) | Melanotan II |
|---|---|---|
| Class | α-MSH analogue (MC1R agonist) | Melanocortin agonist |
| Research category | dermatology and photoprotection | pigmentation and melanocortin signalling |
| Evidence level | High | Low |
| Overall status | Approved (Rx) — erythropoietic protoporphyria (as afamelanotide implant) | Not approved — regulatory warnings issued |
| FDA | Approved (Rx) — EPP | Not approved; warnings issued |
| EMA | Approved (Rx) — EPP | Not approved |
| WADA | Check current list | Check current list |
| Mechanism studied | Melanotan I → MC1R → Eumelanin synthesis → Photoprotection | Melanotan II → MC1R–MC5R → Melanogenesis → Central MC4R signalling |
| Molecular weight | 1,646.8 g/mol | 1,024.2 g/mol |
| Sizes in stock | 10mg | 10mg |
Where the research overlaps
Both compounds are studied within Melanocortin research. Melanotan I (Afamelanotide) is classed as α-msh analogue (mc1r agonist), while Melanotan II is melanocortin agonist. Evidence is rated high for Melanotan I (Afamelanotide) and low for Melanotan II.
For a full write-up, read Melanocortin Peptides: Melanotan, PT-141, Setmelanotide.
FOR RESEARCH USE ONLY.Not for human or veterinary use. Not intended to diagnose, treat, cure, or prevent any disease.